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Abstract 
Background: Access and adherence to artemisinin-based combination therapy (ACT) are key challenges to effec-
tive malaria treatment. A secondary analysis of the Sierra Leone malaria Knowledge, Attitudes, and Practices (mKAP) 
survey was conducted to investigate access and adherence to ACT for the treatment of fever in children under-five.
Methods: The mKAP was a nationally representative, two-stage cluster-sample survey, conducted in 2012. Thirty 
primary sampling units per district were randomly selected using probability proportionate to size, based on national 
census estimates; 14 households were subsequently randomly selected and enrolled per sampling unit. The analysis 
was restricted to children under-five with fever in the past two weeks. Factors associated with access and adherence 
were assessed using multivariate logistic regression.
Results: Of 5169 enrolled households, 1456 reported at least one child under-five with fever in the past two weeks. 
Of the 1641 children from these households, 982 (59.8%) received any treatment for fever and were analysed for 
access to ACT; 469 (47.6%) received ACT and 466 were analysed for treatment adherence. Only 222 (47.4%) febrile 
children received ACT and completed 3-day treatment. In an adjusted analysis, factors associated with ACT access 
included knowledge of ACT (odds ratio [OR] 2.78, 95% CI 2.02–3.80; p < 0.001), knowledge of insecticide-treated nets 
(ITNs) (OR 1.84, 95% CI 1.29–2.63; p = 0.001), source of care (public health facility vs. other; OR 1.86, 95% CI 1.27–2.72, 
p = 0.001), geographic region (East vs. West; OR 2.30, 95% CI 1.20–4.44; p = 0.025), and age (24–59 vs. 0–23 months; 
OR 1.45, 95% CI 1.07–1.96; p = 0.016). The only factor associated with ACT adherence was time to treatment; children 
treated within 24 h were less likely to adhere (OR 0.55, 95% CI 0.34–0.89; p = 0.015).
Conclusions: In 2012, access and adherence to ACT remained low in Sierra Leone. Knowledge of ACT and ITNs, and 
seeking care in the public sector, were most strongly associated with ACT access. National surveys provide important 
information on anti-malarial access and could be expanded to measure treatment adherence.
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Background
Malaria remains a serious health problem in sub-Saharan 
Africa and is particularly dangerous for children under-
five [1–3]. Prompt access to effective treatment is criti-
cal to malaria control. The World Health Organization 
(WHO) malaria treatment guidelines recommend that all 
laboratory-confirmed malaria cases be treated promptly 
(within 24 h of onset) using artemisinin-based combina-
tion therapy (ACT) [4]. Despite this recommendation, 
access to prompt and effective treatment remains sub-
optimal (on average, 65%) across sub-Saharan Africa [3]; 
with access to ACT influenced by availability, afford-
ability, and acceptability [5]. Weak health systems are 
adversely impacted during global public health emergen-
cies, such as Ebola and COVID-19, leading to disruptions 
in service provision, supply chain, and health-seeking 
behaviour [6, 7]. During the Ebola outbreak 2014–2015 
in Sierra Leone, pre-existing gaps in reporting and ser-
vice delivery worsened [8], and changes to service deliv-
ery had a lasting impact on access in  neighbouring 
Liberia [9]. Although access to ACT is essential, multiple 
factors influence the effectiveness of treatment, including 
the efficacy of ACT regimens, targeted testing and treat-
ment, and patient (or caregiver) adherence to treatment 
[10, 11].
In Sierra Leone, malaria is the leading cause of morbid-
ity and mortality in children under-five, accounting for 
47% of outpatient visits [12]. Although amodiaquine plus 
artesunate (AQ + AS) was recommended as the first-line 
treatment for uncomplicated malaria in 2004 [13], access 
to ACT remained low, with only 19.2% of children with 
fever receiving ACT in 2010 [14]. Furthermore, prob-
able adherence to co-packaged AQ + AS in Sierra Leone 
was reported to be only 48.7% in 2008 [15]. In the 2016 
Malaria Indicator Survey (MIS), 40% of children aged 
6–59 months tested positive for malaria; parasite preva-
lence was twice as high in rural compared to urban areas 
(49% vs. 25%) and was highest in the northern region 
(52%) [16].
In 2010, the government of Sierra Leone recognized 
the importance of improving access to essential medica-
tions, including anti-malarials, to reduce childhood mor-
bidity and mortality. Two initiatives were rolled out to 
improve access to health care: (1) The Free Health Care 
Initiative (FHCI), which provides services and medica-
tions free of charge to pregnant women, lactating moth-
ers and children under five at government health facilities 
along with supportive supply-side interventions, such 
as improved drugs and medical supply chains; health 
workforce strengthening; governance; infrastructure 
for service delivery; communication; monitoring and 
evaluation; and health financing [17]; and (2) a malaria 
treatment policy advocating for free malaria testing and 
treatment with ACT for all malaria cases [18].
These initiatives only addressed health system fac-
tors that impact access and targeting of ACT, steps at 
the beginning of the effectiveness pathway, and did not 
focus on the quality of care provided [10, 11, 19]. To be 
truly effective, health workers must follow malaria treat-
ment guidelines, and patients and caregivers must adhere 
to the prescribed ACT regimens. If these last steps of the 
pathway, focusing on adherence, are not realized, effec-
tive treatment and control of malaria cannot be achieved. 
Therefore, it is critical to measure and understand fac-
tors associated not only with access, but also adherence 
to ACT.
Although a number of national surveys between 2013 
and 2016 documented access to ACT in Sierra Leone, 
ranging from 77–97% [14, 16, 20, 21], none of these sur-
veys measured treatment adherence nor factors asso-
ciated with access and adherence to ACT. In 2012, a 
nationwide malaria knowledge, attitudes, and practices 
(mKAP) survey was carried out in Sierra Leone, which 
included not only questions about treatment access but 
also treatment adherence [22]. To further explore access 
and adherence to ACT, a secondary analysis of the mKAP 
dataset was conducted to quantify, and determine factors 




The mKAP was conducted in 2012 by Catholic Relief 
Services in partnership with the National Malaria Con-
trol Programme (NMCP), supported by Statistics Sierra 
Leone. The primary objective of the survey was to gather 
information to inform and update the national malaria 
communication strategy. Additionally, data from the sur-
vey was used to establish a baseline for malaria control 
activities that were to be subsequently implemented with 
support from the Global Fund to Fight AIDS, Tuberculo-
sis, and Malaria [22]. This study is a secondary analysis of 
a subset of data collected from the mKAP survey.
The mKAP survey was a nationally representative two-
stage cluster sample survey conducted in all 14 districts 
of Sierra Leone. Thirty primary sampling units (PSU) per 
Keywords: Malaria, Antimalarial, Artemisinin-based combination therapy (ACT), Sierra Leone, Prompt treatment, 
Access, Adherence, Treatment completion
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district were randomly selected using probability propor-
tional to size (PPS) based on estimates from the National 
Census [23]. This resulted in 5880 randomly chosen 
households (14 households per PSU; 420 households per 
district). The questionnaire was based on the Roll Back 
Malaria standardized guidelines for core population-
level indicators [24]. All respondents answered ques-
tions about household demographics and assets, malaria 
knowledge and prevention practices, recent pregnancy 
experiences, and whether the household contained one 
or more children aged under-five who had a fever in the 
previous two weeks. Information on fever treatment was 
collected on up to three such children per household. The 
mKAP survey was conducted in 2012 before a question 
about receiving a blood test was universally introduced 
into national surveys, and therefore did not include a 
question on whether the child had “blood taken from his/
her finger or heel for testing.”
Data collection
Data were collected by trained field staff using Apple 
iPhones provided by Catholic Relief Services. The devices 
were programmed using the iFormBuilder mobile plat-
form (Zerion Software, Inc., Herndon, VA, USA) [25]. All 
electronic data were transferred from the Apple devices 
into a cloud database regularly while in the field using the 
local 3G mobile network. Upon completion of the field-
work, any remaining forms that needed to be transferred 
were uploaded via wireless internet connections at Sta-
tistics Sierra Leone and Catholic Relief Services offices in 
Freetown.
Paper questionnaires were provided to teams to use 
only as a backup in case of electronic equipment failure. 
When necessary, data entered onto paper forms were 
then entered into an iPhone as soon as it was possible. 
Backup files of the database were stored on two exter-
nal servers (iFormBuilder and a specially created Google 
email account). Additionally, data were stored on the 
iPhones until completion of the study. For quality con-
trol, validation and built-in skip logic were written into 
the iFormBuilder program.
Outcome variables and predictors
The objectives of this study were: (1) to quantify the level 
of access and adherence to ACT in children less than 
five in Sierra Leone, (2) to assess factors associated with 
access to ACT for children under-five with fever in the 
two weeks preceding the survey, and (3) to identify fac-
tors associated with adherence to ACT in those children 
that received ACT for their fever. Access was defined 
as receiving ACT for the treatment of the most recent 
fever. Adherence was defined as taking the treatment 
for the recommended 3 days. The methodology used to 
assess adherence was similar to that used in two previ-
ous cross-sectional household studies in Kenya, which 
utilized a self-report question to assess whether the dura-
tion of treatment with ACT was correct (i.e. 3 days) [26, 
27]. Those taking ACT for 3 days were considered to have 
completed treatment and were classified as adherent, 
while those taking ACT for less than 3 days or more than 
3 days were classified as non-adherent.
Using the available variables from the survey dataset, 
along with the factors identified in the ACT adherence 
literature, a list of a priori predictors were identified and 
evolved into a conceptual framework (Fig.  1). Four cat-
egories of potential predictors of access and adherence 
were identified: (1) socioeconomic status (i.e. wealth class 
and education); socio-demographic characteristics (i.e. 
child age, religion, household size, place of residence); 
(2) knowledge of malaria (i.e. knowledge of protective 
measures and treatments); and (3) health practices (i.e. 
accesses prompt treatment for fever, ITN utilization, and 
source of health care).
Data analysis
Stata Version 12 (StataCorp, College Station, TX USA) 
and Excel (Microsoft Corp. Redmond, WA, USA) were 
used for data processing and analysis. In all analyses, 
the “svy” commands were used to account for the survey 
design, including clustering by PSU and stratification by 
the location of the PSU (urban/rural). Descriptive statis-
tics were used to summarize household and respondent 
characteristics as well as treatment-seeking behaviour for 
children with fever. Household socioeconomic status was 
based on a principal component analysis (PCA) of house-
hold assets, split into tertiles [28].
Logistic regression models were used to estimate the 
crude and adjusted odds ratios and their 95% confidence 
intervals to assess the strength of the association between 
the a priori predictors and the two outcomes (access and 
adherence to ACT). All predictor variables were included 
in multivariable analyses regardless of p-values, with the 
exception that for any pair of covariates identified to be 
strongly correlated (Pearson’s correlation r ≥ 0.8), one 
was removed from the final model. Associations between 
the predictors and outcomes were considered significant 
if the p-value was < 0.05.
Ethical considerations
The original study protocol was approved by the Sierra 
Leone Ethics and Scientific Review Committee prior to 
the commencement of activities. Ethical approval to con-
duct this secondary analysis of the mKAP data set was 
obtained from the London School of Hygiene & Tropi-
cal Medicine. Permission to use this data for secondary 
Page 4 of 13Banek et al. Malar J           (2021) 20:56 




Of 5169 enrolled households, 1456 reported at least one 
child under-five with fever in the past two weeks and 
were included in the analysis (Fig.  2). Access to ACT 
was assessed in 1641 children residing in these house-
holds who had a recent history of fever and data on treat-
ment available. Of these children, factors associated with 
access to ACT were estimated for children whose car-
egiver sought and received any treatment for their child’s 
fever (n = 982). Factors associated with adherence to 
ACT were assessed for children who received ACT and 
had data on treatment duration (n = 466).
Characteristics of households and their children
Overall, households that reported fever in a child 
under-five within the past two weeks were similar to 
other households, as were the adult respondents from 
these households (Table  1). Households with febrile 
children were primarily located in rural areas (87.6%), 
practiced the Islamic faith (81.0%), and owned at least 
one bed net of any type (87.2%). The average age of the 
adult caregiver respondents was 39.2 years, and 66.8% 
reported not having any formal education. Three out 
of four adult respondents (76.6%) reported sleeping 
under an insecticide-treated net (ITN) the previous 
night. Although most respondents were knowledgeable 
about malaria, some information gaps were identified, 
specifically regarding the prevention and treatment of 
malaria. Only 606 (41.8%) respondents were aware that 
ACT was the recommended treatment for malaria.
Treatment for children under‐five with fever
Of the 1641 children under-five with a fever episode 
in the last 2 weeks, care was sought for 1038 (63.4%) 
(Table  2). The majority of children (82.2%) were taken 
to a public health facility. Of those children for whom 
treatment was sought, most (n = 982) received any 
treatment, the majority of which were anti-malarials 
(n = 780). Of these children, 469 (47.6%) received ACT, 
most of whom (n = 314; 67.8%) were treated within 24 h 
of onset. Only 222 (47.4%) children with fever received 
ACT and completed 3-day treatment, and only 137 
(31.6%) received prompt treatment (within 24 h) with 
ACT and completed the 3-day treatment.
Fig. 1 Conceptual framework. A summary of hypothesized socio-demographic factors associated with access and adherence to ACT 
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Factors associated with access
In a multivariate analysis restricted to children who 
received any treatment for fever (n = 982), five factors 
were found to be significantly associated with receiv-
ing ACT (access), including geographic region, the 
knowledge that ITNs protect against malaria, knowl-
edge of ACT, older child age, and seeking care at a 
public health facility (Table  3). ACT access was high-
est in the eastern region. Knowledge of ACT was the 
strongest predictor; children with caregivers who were 
knowledgeable about ACT had almost three times the 
odds of receiving an artemisinin-based combination 
for treatment of fever than children whose caregivers 
lacked this knowledge (OR: 2.78; 95% CI 2.02–3.80; 
p < 0.001). Similarly, children whose caregiver knew 
that ITNs provide protection from malaria were more 
likely to receive ACT (OR: 1.84; 95% CI 1.29–2.63; 
p = 0.001). Children treated at a public health facility 
Fig. 2 mKAP survey profile
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had nearly twice the odds of receiving an artemisinin-
based combination compared to those treated else-
where (OR: 1.86; 95% CI 1.27–2.72; p = 0.001), and 
older children (24–59 months) were more likely to 
receive ACT than children aged 0–23 months (OR: 
1.45; 95% CI 1.07–1.96; p = 0.016).
Factors associated with adherence
In a multivariate analysis restricted to children who 
received ACT and had data on treatment duration 
(n = 466), only one factor was found to be significantly 
associated with adherence (Table  4). Children receiv-
ing ACT within 24 h of symptom onset were less likely 
Table 1 Household and  individual-level characteristics of  survey participants, stratified by  the  presence or  absence 
of a child under five with fever in the preceding 2 weeks
a Secondary or higher includes technical and vocational school
Variable Categories Under-five Households with fever 
(N = 1456)
Under-five Households 
without fever (N = 1199)
n(%) 95% CI n(%) 95% CI
Household
 Location Urban 191 (12.4%) 10.6–14.4% 184 (14.8%) 12.8–17.0%
Rural 1265 (87.6%) 85.6–89.4% 1015 (85.2%) 83.0–87.2%
 Region of Sierra Leone North 672 (46.9%) 41.4–52.5% 368 (30.6%) 25.8–35.9%
South 371 (25.4%) 21.1–30.3% 427 (35.7%) 30.4–41.4%
East 291 (19.5%) 15.7–24.1% 236 (19.8%) 15.9–24.5%
West 122 (8.2%) 5.8–11.3% 168 (13.9%) 10.6–18.0%
 Number of household residents 1–5 430 (29.3%%) 26.5–32.2% 440 (36.6%) 33.6–39.8%
6–10 795 (54.7%) 51.8–57.5% 602 (50.4%) 47.3–53.5%
11+ 231 (16.1%) 13.9–18.5% 157 (12.9%) 11.0–15.2%
 Religion Christian 284 (19.0%) 16.2–22.2% 261 (21.9%) 18.9–25.4%
Muslim 1172 (81.0%) 77.8–83.8% 938 (78.1%) 74.8–81.2%
 Socio-economic status 1 (poorest) 508 (35.4%) 31.9–39.0% 400 (33.4%) 30.0–37.1%
2 532 (36.2%) 33.3–39.1% 410 (34.2%) 31.2–37.4%
3 (least poor) 416 (28.5%) 25.2–31.9% 389 (32.3%) 28.6–36.3%
 Ownership of bed nets Own any net 1272 (87.2%) 10.1–15.1% 1045 (86.9%) 84.4–89.1%
Net is an ITN 1214 (83.1%) 80.5–85.5% 989 (82.2%) 79.2–84.9%
Mean ITNs 2.6 2.5–2.8 2.5 2.4–2.6
Household adult respondents
 Mean age (years) 39.2 38.4–40.1 38.7 37.8–39.6
 Gender Male 684 (47.1%) 44.0–50.2% 577 (48.2%) 45.0–51.5%
Female 772 (52.9%) 49.8–56.0% 622 (51.8%) 48.5–55.0%
 Education None 967 (66.8%) 63.9–69.6% 779 (64.7%) 61.4–67.9%
Primary 173 (11.8%) 10.1–13.8% 124 (10.7%) 8.9–12.7%
Secondary/highera 279 (18.7%) 16.4–21.2% 277 (23.0%) 20.3–25.9%
Arabic/Other 37 (2.7%) 1.9–3.8% 19 (1.7%) 1.0–2.8%
 ITN use previous night Respondent 1129 (76.6%) 73.7–79.3% 913 (76.2%) 72.9–79.2%
Knowledge of malaria-related topics
 Ever hear of the illness called “Malaria” Yes 1492 (98.1%) 97.0–98.8% 1167 (97.4%) 96.1–98.3%
 At least one sign or symptom of malaria Yes 1374 (94.2%) 92.5–95.6% 1116 (93.0%) 91.1–94.6%
 All are susceptible to malaria Yes 1065 (73.2%) 70.3–75.9% 884 (73.4%) 70.3–76.3%
 At least one malaria protective measure Yes 1244 (85.2%) 82.6–87.5% 1026 (85.4%) 82.7–87.8%
 ITNs can prevent malaria Yes 865 (59.6%) 56.3–62.9% 741 (60.9%) 57.1–64.5%
 At least one antimalarial drug Yes 1268 (86.9%) 84.7––88.8% 1021 (85.1%) 82.5–87.3%
 Recommended treatment with ACTs Yes 606 (41.8%) 38.5–45.3% 527 (43.7%) 40.2–47.2%
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to complete treatment than those who received ACT 
treatment beyond this window (OR: 0.55; 95%CI 0.34–
0.89; p = 0.015). Due to collinearity with ‘knowledge 
of ACT,’ ‘knowledge of at least one anti-malarial’ and 
‘knowledge of at least one sign or symptom of malaria’ 
were removed from the multivariable models. Similarly, 
ITN use was retained, while ITN ownership and knowl-
edge of any malaria protective measures were removed. 
As knowledge of the term ‘malaria’ was collinear with 
both knowledge of ACT and ITN utilization, it was 
removed from both final multivariable models.
Discussion
The pathway to effective malaria case management 
depends on timely access to ACT and patient (or car-
egiver) adherence to treatment regimens. ACT has 
been recommended as the first-line treatment in Sierra 
Leone since 2004; however, in 2012, uptake remained 
suboptimal. To further investigate access to ACT and 
adherence to treatment guidelines in Sierra Leone, a 
secondary analysis of the national 2012 mKAP survey 
was undertaken. In a previous nationwide survey con-
ducted in 2010, only 19.2% of febrile children received 
ACT, and only 50.3% received any anti-malarial within 
Table 2 Treatment and treatment-seeking behaviors for children under-five with fever (n = 1641)
a The denominator is the number seeking treatment for the fever in the last 2 weeks (n = 1038)
b Other sources of treatment include: Community Health workers [Community Health Worker (CHW), Traditional Birth Attendant (TBA), Blue Flag Volunteer 
(BFV)] = 39; Informal Health workers (drug peddler, traditional healer) = 31; Drug shops/Pharmacy = 96; private clinics/doctors = 9 and self-treatment = 9
c Other drugs received include other antimalarial–mono-therapy: quinine and amodiaquine (4), antibiotics (34), antidiarrheal/ORS (17), other antipyretic (7), cough 
medicine (2), deworm (1), vitamins (12), iron (16), unnamed syrup (6), injection (11), routine medication (10), unspecified/unknown (16)
d The denominator is the number who received ACT (n = 469)
e The denominator is the number who received ACT and who have information on the timing and duration of treatment (n = 433)
Observations
n/N % Linearized SE 95% CI
Treatment seeking for fever
 Caregiver sought treatment 1038/1641 63.4 % 1.67% 60.1–66.6%
 Caregiver sought prompt treatment (≤ 24 h) 571/1038 55.9% 1.87% 52.2–59.6%
First treatment  sourcea
 Public health facility 854/1038 82.2% 1.48% 79.1–84.9%
 Otherb 184/1038 17.8% 1.48% 15.1–20.9%
Treatment of fever
 Received any treatment 982/1038 94.6% 0.83% 92.7–96.1%
Type of treatment
 Artemisinin combination therapy (ACT) 469/982 47.6% 2.11% 43.4–51.7%
 Chloroquine 472/982 48.7% 2.19% 44.5–53.1%
 Sulfadoxine-pyrimethamine (SP) 153/982 15.0% 1.37% 12.5–17.9%
 Paracetamol 770/982 78.4% 1.67% 74.3–80.9%
 Herbs 141/982 14.4% 1.36% 11.6–17.0%
 Otherc 136/982 13.5% 1.32% 11.1–16.3%
ACT treatment  timed
 Received ACT same/next day ( within 24 h) 314/469 67.8% 2.33% 63.0–72.2%
 Received ACT on day 2 93/469 19.4% 2.00% 15.8–23.7%
 Received ACT 3 + days 29/469 6.0% 1.07% 4.2–8.5%
 ACT treatment time unknown 33/469 6.8% 1.21 4.8–9.6%
ACT  durationd
 Took ACT for 3 days (correct duration) 222/469 47.4% 2.56% 42.4–52.4%
 Did not take ACT for 3 days 244/469 52.0% 2.53% 47.1–57.0%
 ACT duration unknown 3/469 0.57% 0.03% 0.19–1.74%
 Mean duration of ACT treatment (days) 3.62 0.80 3.47–3.78
Prompt and effective treatment with ACT e
 Children who received ACT < 24 h & Completed 3-day 
treatment course
137/433 31.6% 2.57% 27.3–37.4%
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Table 3 Factors associated with receiving an ACT among febrile children under-five who received any treatment (n = 982)
Variable n/N % Unadjusted analysis Adjusted analysis
OR (95% CI) p value OR (95% CI) p value
Location
 Rural 386/835 46.3% Ref 0.181 Ref 0.899
 Urban 83/147 54.9% 1.41 (0.85–2.33) 1.03 (0.63–1.69)
Region
 West 36/75 47.8% Ref 0.253 Ref 0.025
 North 203/452 45.0% 0.89 (0.51–1.56) 1.20 (0.64–2.26)
 South 125/268 45.9% 0.93 (0.51–1.70) 1.48 (0.79–2.83)
 East 105/187 56.4% 1.41 (0.75–2.66) 2.30 (1.20–4.44)
Household size
 1–5 146/269 52.2% Ref 0.058 Ref 0. 178
 6–10 257/548 47.6% 0.83 (0.59–1.17) 0.95 (0.68–1.33)
 11+ 66/165 39.9% 0.61 (0.41–0.91) 0.69 (0.46–1.04)
Household religion
 Muslim 375/796 46.9% Ref 0.402 Ref 0.579
 Christian 94/186 50.7% 1.17 (0.81–1.67) 0.90 (0.62–1.30)
Socio-economic status
 1 (poorest) 131/317 41.0% Ref 0.001 Ref 0.237
 2 175/382 46.1% 1.23 (0.87–1.73) 1.00 (0.68–1.47)
 3 (least poor) 163/283 57.0% 1.91 (1.31–2.77) 1.41 (0.88–2.24)
Respondent education
 None 290/644 45.1% Ref 0.059 Ref 0.930
 Primary 63/123 51.2% 1.28 (0.87–1.89) 1.03 (0.68–1.58)
 Secondary or higher 107/196 53.8% 1.42 (0.99–2.03) 1.00 ( 0.66–1.50)
 Arabic school or Other 9/19 47.9% 1.12 (0.44–2.87) 1.41 (0.49–4.08)
Everyone is at risk
 No 120/250 47.4% Ref 0.948 Ref 0.380
 Yes 349/732 47.6 1.01 (0.73–1.39) 0.85 (0.60–1.22)
ITNs protect from malaria
 No 129/370 35.0% Ref < 0.001 Ref 0.001
 Yes 340/612 55.2% 2.29 (1.66–3.15) 1.84 (1.29–2.63)
Under 5 slept under ITN
 No 119/287 40.2% Ref 0.009 Ref 0.061
 Yes 350/695 50.6% 1.53 (1.11–2.10) 1.41 (0.98–2.02)
Knowledge of ACTs
 No 187/537 34.7% Ref < 0.001 Ref < 0.001
 Yes 282/445 63.0% 3.20 (2.36–4.35) 2.78 (2.02–3.80)
Child age (months)
 0–23 months 136/321 42.6% Ref 0.047 Ref 0.016
 24–59 months 333/661 49.9% 1.34 (1.00–1.79) 1.45 (1.07–1.96)
Prompt treatment (< 24 h)
 No 209/440 47.2% Ref 0.842 Ref 0.866
 Yes 260/542 47.9% 1.03 (0.77–1.37) 1.03 (0.76–1.38)
Public health facility
 No 57/159 36.4% Ref 0.004 Ref 0.001
 Yes 412/823 49.7% 1.73 (1.19–2.52) 1.86 (1.27–2.72)
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Table 4 Factors associated with  adherence to  ACTs among  febrile children under-five who received treatment 
with an artemisinin-based combination (n = 466)
Variable n/N % Unadjusted analysis Adjusted analysis
OR (95% CI) p value OR (95% CI) p value
Location
 Rural 178/385 46.2% Ref 0.233 Ref 0.245
 Urban 44/81 55.3% 1.44 (0.79–2.64) 1.49 (0.76–2.95)
Region
 West 11/35 30.1% Ref 0.355 Ref 0.211
 North 98/202 47.9% 2.13 (0.83–5.50) 2.58 (0.99–6.77)
 South 60/124 49.3% 2.26 (0.87–5.89) 2.83 (1.04–7.68)
 East 53/105 50.8% 2.40 (0.91–6.32) 2.76 (1.04–7.32)
Household size
 1–5 63/144 45.3% Ref 0.487 Ref 0.620
 6–10 122/256 47.3% 1.08 (0.72–1.62) 1.13 (0.73–1.73)
 11 + 37/66 54.2% 1.43 (0.79–2.59) 1.35 (0.73–2.50)
Household religion
  Muslim 172/373 46.0% Ref 0.158 Ref 0.058
 Christian 50/93 54.7% 1.42 (0.87–2.30) 1.61 (0.98–2.65)
Socio-economic status
 1 (poorest) 62/131 46.5% Ref 0.883 Ref 0.930
 2 83/175 47.0% 1.02 (0.64–1.63) 1.07 (0.66–1.75)
 3 (least poor) 77/160 49.4% 1.13 (0.68–1.86) 1.12 (0.60–2.08)
Respondent education
 None 138/288 48.1% Ref 0.984 Ref 0.854
 Primary 30/63 48.5% 1.02 (0.58–1.80) 0.87 (0.46–1.64)
 Secondary or higher 50/106 46.5% 0.94 (0.57–1.54) 0.80 (0.46–1.38)
  Arabic or other 4/9 42.3% 0.79 (0.18–3.49) 0.74 (0.17–3.26)
Know everyone is at risk
 No 60/120 51.3% Ref 0.390 Ref 0.329
 Yes 162/346 46.4% 0.82 (0.53–1.29) 0.79 (0.49–1.27)
Know ITNs protect
 No 62/128 48.4% Ref 0.844 Ref 0.943
 Yes 160/338 47.4% 0.96 (0.63–1.47) 0.98 (0.63–1.54)
U5 slept under ITN
 No 58/118 48.8% Ref 0.779 Ref 0.829
 Yes 164/348 47.3% 0.94 (0.61–1.44) 0.95 (0.60–1.50)
Knowledge ACTs
 No 88/187 46.9% Ref 0.805 Ref 0.866
 Yes 134/279 48.2% 1.05 (0.70–1.57) 1.04 (0.67–1.60)
Child age (months)
 0–23 months 60/135 43.9% Ref 0.276 Ref 0.270
 24–59 months 162/331 49.2% 1.24 (0.84–1.81) 1.26 (0.83–1.90)
Prompt treatment (< 24 h)
 No 102/207 49.5% Ref 0.744 Ref 0.150
 Yes 119/258 45.9% 1.05 (0.79–1.39) 1.25 (0.92–1.70)
Public health facility
 No 28/57 48.3% Ref 0.926 Ref 0.951
 Yes 194/409 47.6% 0.97 (0.55–1.74) 0.98 (0.53–1.81)
ACT within 24 h
 No 85/154 55.0% Ref 0.047 Ref 0.015
 Yes 137/312 44.1% 0.65 (0.42–0.99) 0.55 (0.34–0.89)
Data for ACT duration was available for 466 children out of the 469 that received ACT 
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24 h [14]. Assuming that a large proportion of febrile 
illness in children under five in Sierra Leone is due to 
malaria, these results suggest that challenges to deliv-
ering prompt and effective malaria treatment still 
remained in 2012.
In 2012, most children under-five with fever in the 2 
weeks before the survey did not receive an artemisinin-
based combination. ACT access varied geographically 
and was highest in the eastern region of the country. 
Similar to findings reported from Thailand, Kenya, and 
Uganda [29–31], this study found that children were 
more likely to receive ACT if their caregiver had prior 
knowledge of ACT and ITNs, suggesting that health 
education interventions could improve patient access to 
ACT. Additionally, this analysis found that seeking care 
from a public health facility doubled the odds of receiv-
ing ACT, suggesting that price or limited availability may 
impact access to ACT in the private sector. This is simi-
lar to other studies in sub-Saharan Africa, which have 
reported improved access to ACT for children treated in 
the public sector [32, 33].
This study also demonstrates a difference in access 
based on age, with older children (2–4 years) more likely 
to receive ACT than younger children (< 2 years). While 
removing user-fees removes the cost barrier of access-
ing care for individuals, it can strain weak health systems 
when demand increases. Higher patient loads require 
more resources to provide adequate service delivery. 
Although Sierra Leone had a relatively high availability 
of amodiaquine + artesunate (the ACT of choice at the 
time) compared to other post-conflict countries [34], the 
number of infant doses has often been insufficient due 
to improper forecasting and provision of pediatric for-
mulations [35, 36]. Such challenges could be even more 
significant with the recent Ebola outbreak and ongoing 
pandemic [7, 8].
Of those febrile children who received artemisinin-
based combination, less than half completed the recom-
mended 3-day course of treatment (47.6%). However, 
no significant association between knowledge of ACT, 
malaria, or prevention practices and adherence was 
found, despite suggestions that patient knowledge, atti-
tudes, and beliefs may be strong predictors of adherence 
[15, 31, 37–40]. Although Bruxvoort et al. reported that 
age, higher household income, higher education level, 
malaria knowledge, and treatment-seeking behavior are 
factors facilitating anti-malarial adherence [41], none of 
the a priori socioeconomic or demographic factors were 
associated with adherence in this study.
Unlike the findings reported for access, this analy-
sis found no association between the source of care and 
treatment adherence. Unexpectedly, poor adherence 
to ACT was associated with accessing ACT promptly 
(within 24 h from the onset of symptoms). Lemma et al.. 
reported similar results; participants that delayed 1 day 
before seeking treatment were more adherent than those 
seeking prompt treatment (OR: 5.39; 95% CI 1.83–15.88) 
[37]. In contrast, a study in Uganda reported that prompt 
access to ACT was associated with higher treatment 
adherence [30]. Similarly, patients in Kenya seeking treat-
ment greater than 1 day after the start of fever were 27% 
less likely to be adherent [31]. Given these mixed results, 
the association between prompt treatment for fever and 
lower ACT adherence should be interpreted with cau-
tion. Those accessing treatment early may have had lower 
parasite loads, which was cleared more quickly, resulting 
in fewer symptoms and possibly lower treatment adher-
ence. Moreover, as the mKAP survey did not capture 
information on confirmatory malaria diagnosis, the child 
may have had a non-malaria febrile illness, and their 
symptoms may have resolved at the same time as receiv-
ing ACT, thus leading the caregiver to discontinue the 
treatment.
National cross-sectional household surveys such as the 
Demographic Health Survey (DHS), Multiple Indicator 
Cluster Survey (MICS), and the Malaria Indicator Survey 
(MIS) routinely collect information on the treatment of 
fever. These surveys including questions on treatment-
seeking behavior for fever, medications received for that 
fever, and how soon after the onset of symptoms, the 
treatment was initiated. Additionally, since 2013, most 
surveys have gathered information on whether a blood 
test was received. However, the test question is not 
malaria-specific, nor is information on the test result col-
lected due to concerns about the reliability of the data 
[42, 43]. Without this vital specific information, caution 
should be taken when interpreting results on fever case 
management from these surveys, as these data would 
represent the treatment of fever and not necessarily 
malaria. Ashton et al.. recently found that caregiver recall 
surrounding testing and diagnosis to be valid; therefore, 
the recommendation regarding confirmed malaria cases 
may need to be reviewed [44].
The fever case management sections of these national 
surveys could be expanded to include questions related to 
ACT treatment adherence, such as duration and/or com-
pletion of treatment, as was done in this study. Including 
these additional questions would allow a population-level 
estimate of adherence to be measured, as well as infor-
mation on access to ACT, providing a more complete pic-
ture of the malaria treatment pathway. Collecting ACT 
adherence data through national surveys would be sim-
ple to implement, sustainable, and cost-effective. How-
ever, the use of national surveys to assess ACT adherence 
has several limitations: (1) the method assumes that 
respondents know and recognize which anti-malarial or 
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artemisinin-based combination was prescribed for their 
child; (2) the data is relying on self-reported outcomes; 
and (3) unless surveys collect information about diag-
nostic testing specifically for malaria along with those 
test results, then the utility of adherence data would be 
limited as it would apply only to children with fever who 
may or may not have malaria.
Although this was a national survey, which allows 
generalizability of the findings to the entire country, 
there were some limitations. First, the data presented 
here were collected in 2012. Despite the delay in report-
ing these results, ACT adherence at the national level 
remains unknown in 2020, and factors impacting access 
and adherence to ACT have yet to be evaluated in Sierra 
Leone. Second, the study cannot provide a causal rela-
tionship between improved access and government pro-
grams rolled out to improve access to health services. 
However, the successful implementation of the FHCI in 
certain districts may have contributed to better access 
to medicines and services [19]. Third, the analysis was 
limited to the variables collected and may not have cap-
tured all the factors plausibly associated with receiving 
or completing treatment with ACT. In particular, this 
secondary analysis did not contain information on ACT 
and malaria rapid diagnostic tests stock-outs, confirma-
tory diagnosis of malaria, the quality of care at the health 
facility (including if the health worker provided informa-
tion on how to administer the medication), or treatment 
completion. Additionally, questions on the number of 
tablets taken or whether treatment was completed were 
not included in this survey and would have contributed 
to a more precise quantification of adherence. Finally, 
although the sample size was large, it may not have pro-
vided the optimal power needed to detect associations 
between adherence and the a priori socioeconomic or 
demographic factors identified.
Conclusions
This study demonstrates that poor access and adher-
ence to ACT remained key challenges to ensuring 
effective malaria case management in Sierra Leone 
in 2012 and continues to be a challenge in the face of 
public health emergencies such as Ebola and COVID-
19. While efforts have been made to improve access 
to key health services in Sierra Leone, such as malaria 
treatment, further emphasis on ACT adherence is still 
needed. Optimizing the supply chain, implementa-
tion of the Free Health Care Initiative, and scaling up 
malaria communication campaigns to include messages 
on adherence could improve malaria treatment effec-
tiveness in Sierra Leone. Finally, national household 
surveys could be expanded to capture key indicators on 
ACT access and adherence to help guide malaria case 
management in the future.
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